 <h1>Hydrochlorothiazide / valsartan Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to hydrochlorothiazide / valsartan: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Drugs with direct action on the renin-angiotensin system can cause injury or death to the developing fetus. Discontinue valsartan/hydrochlorothiazide therapy as soon as possible when pregnancy occurs.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, hydrochlorothiazide / valsartan may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking hydrochlorothiazide / valsartan:</p><p>
<i>Less common</i>
</p><ul>
<li>Cold or flu-like symptoms</li>
<li>difficulty with swallowing</li>
<li>sore throat</li>
<li>tender or swollen lymph nodes in the neck</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Bloating or stomach pain</li>
<li>blurred vision</li>
<li>chills</li>
<li>eye pain</li>
<li>fainting</li>
<li>fever</li>
<li>flushing</li>
<li>itching, pain, redness, or swelling of the eye or eyelid</li>
<li>joint stiffness or swelling, especially if sudden</li>
<li>nausea</li>
<li>skin rash or hives</li>
<li>trouble breathing</li>
<li>vomiting</li>
<li>watering of the eyes</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Confusion</li>
<li>dark urine</li>
<li>decreased urine output</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>fast or irregular heartbeat</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>light-colored stools</li>
<li>lightheadedness</li>
<li>muscle cramps, spasms, pain, or stiffness</li>
<li>nervousness</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>persistent non-healing sore</li>
<li>pink growth</li>
<li>reddish patch or irritated area</li>
<li>seizures</li>
<li>shiny bump</li>
<li>thirst</li>
<li>weakness or heaviness of the legs</li>
<li>white, yellow or waxy scar-like area</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of hydrochlorothiazide / valsartan may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Cough</li>
<li>diarrhea (mild)</li>
<li>headache</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Anxiety</li>
<li>increased sensitivity to sunlight</li>
<li>increased sweating</li>
<li>redness of the face or neck</li>
<li>reduced sexual performance or drive</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Hair loss or thinning of the hair</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hydrochlorothiazide / valsartan: oral tablet</i></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, fatigue, dizziness</p>
<p><b>Rare</b> (less than 0.1%): Vertigo, tinnitus<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Nausea, diarrhea, rash, acute pulmonary edema, interstitial nephritis or cystitis, anaphylaxis<sup>[Ref]</sup></p><p>Rare cases of interstitial nephritis have been associated with the use of HCTZ.  Although HCTZ has been used to treat nephrogenic diabetes insipidus, a case report in which the drug was believed to have caused this condition has been reported.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Rare</b> (less than 0.1%): Renal insufficiency, azotemia<sup>[Ref]</sup></p><p>In multiple-dose studies in hypertensive patients with stable renal insufficiency and renovascular hypertension, the use of valsartan alone had no clinically significant effects of glomerular filtrate rate, filtration fraction, creatinine clearance, or renal plasma flow.  The use of HCTZ has been associated with the development of pre-renal azotemia.  Pretreatment volume repletion is recommended prior to initiating therapy.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Palpitations, chest pain, angioedema</p>
<p><b>Frequency not reported</b>: Cardiac arrhythmias (including ventricular ectopy and complete AV heart block)<sup>[Ref]</sup></p><p>Chest pain was reported in more than 2% of patients who were taking this combination drug in controlled trials, but this incidence was not significantly different compared with the incidence of chest pain among placebo patients.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Angiotensin II receptor blockade, unlike ACE inhibition, has no impact on the processing of peptides such as bradykinin and substance P, two peptides able to induce cough.</p>
<p></p>
<p>Bronchospasm, dyspnea, and epistaxis have rarely been associated with the use of this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Cough (valsartan component)</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspnea, acute pulmonary edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Erythema annular centrifugum, acute eczematous dermatitis, morbilliform, leukocytoclastic vasculitis, phototoxic dermatitis, subacute cutaneous lupus erythematosus-like condition, pruritus, rash<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Since HCTZ may increase total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, and VLDL lipoprotein cholesterol levels by 50%, and may reduce insulin secretion, it should be used with caution in diabetic patients and in those with hypercholesterolemia.  True glucose intolerance may develop in approximately 3% of patients.  It is typically reversible within six months after discontinuation of therapy.</p>
<p></p>
<p>Hyperuricemia may be an important consideration in patients with a history of gout.  Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Hypokalemia, hyperkalemia, metabolic alkalosis, hyponatremia, hypomagnesemia, hypercalcemia, hyperglycemia, elevated serum uric acid levels, elevated serum cholesterol<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Thiazide diuretics may increase serum cholesterol and triglycerides, resulting in an increased risk of cholesterol gallstone formation.  Reports of bowel strictures associated with thiazide ingestion were reported in the 1960s (although patients in these reports were on a combination HCTZ-potassium product).<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Diarrhea, constipation, appetite changes, dry mouth, dyspepsia, nausea, vomiting, flatulence, pancreatitis, cholecystitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (0.01% to 0.1%): Allergic vasculitis, hemolytic anemia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Glucose intolerance, altered lipid profile<sup>[Ref]</sup></p><p>Use of valsartan alone has not been associated with significant changes in serum lipids or glucose concentrations.  However, use of HCTZ may be associated with increases in total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, and VLDL lipoprotein cholesterol levels by 50%.  In addition, use of HCTZ may be associated with reduced insulin secretion.  Therefore, caution is recommended when giving this combination drug to diabetic patients or those with hypercholesterolemia.</p>
<p></p>
<p>Hyperuricemia may be an important consideration in patients with a history of gout.  Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.</p>
<p></p>
<p>A prospective study of 34 patients who received oral thiazide diuretics for 14 years without interruption revealed significantly increased average fasting blood glucose levels.  Withdrawal of thiazide therapy for 7 months in 10 of the patients resulted in average reductions of 10% in fasting blood glucose and 25% in 2-hour glucose tolerance test values.  A control group was not reported.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, muscle cramps, myalgia</p>
<p></p>
<p>Valsartan:</p>
<p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Neutropenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hematocrit decreased, hemoglobin decreased</p>
<p><b>Rare</b> (0.01% to 0.1%): Immune complex hemolytic anemia</p>
<p><b>Postmarketing reports</b>: Thrombocytopenia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Rare</b> (less than 0.1%): Anxiety, depression, decreased libido, insomnia, paresthesias, somnolence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Rare</b> (less than 0.1%): Impotence, dysuria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Increases in hepatic enzymes (usually reversible)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (less than 0.1%): Abnormal vision, idiosyncratic reactions to hydrochlorothiazide resulting in acute transient myopia and acute angle-closure glaucoma<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Weir MR, Wright JT, Jr  Ferdinand KC, Cook CA, Champion D, Wong S, Jenkins PA, Kong BW "Comparison of the efficacy and metabolic effects of nicardipine and hydrochlorothiazide in hypertensive black men and women." J Hum Hypertens 7 (1993): 141-7</p><p id="ref_2">2. Langtry HD, McClellan KJ "Valsartan hydrochlorothiazide." Drugs 57 (1999): 751-5</p><p id="ref_3">3. Wellington K,  Faulds DM "Valsartan/Hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension." Drugs 62 (2002): 1983-2005</p><p id="ref_4">4. Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980): 1975-6</p><p id="ref_5">5. Kaplan R, Claudio M, Kepes E, Gu XF "Intravenous guanethidine in patients with reflex sympathetic dystrophy." Acta Anaesthesiol Scand 40 (1996): 1216-22</p><p id="ref_6">6. "Product Information. Diovan HCT (hydrochlorothiazide-valsartan)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_7">7. Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996): 1147-115</p><p id="ref_8">8. Oparil S, Dyke S, Harris F, et al. "The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension." Clin Ther 18 (1996): 797-810</p><p id="ref_9">9. Levay ID "Hydrochlorothiazide-induced pulmonary edema." Drug Intell Clin Pharm 18 (1984): 238-9</p><p id="ref_10">10. Klein MD "Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion." Ann Emerg Med 16 (1987): 901-3</p><p id="ref_11">11. Alted E, Navarro M, Cantalapiedra JA, Alvarez JA, Blasco MA, Nunez A "Non-cardiogenic pulmonary edema after oral ingestion of hydrochlorothiazide ." Intensive Care Med 13 (1987): 364-5</p><p id="ref_12">12. Biron P "Thiazide-induced pulmonary edema." Ann Pharmacother 30 (1996): 415-6</p><p id="ref_13">13. Dorn MR, Walker BK "Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy." Chest 79 (1981): 482-3</p><p id="ref_14">14. Hoegholm A, Rasmussen SW, Kristensen KS "Pulmonary oedema with shock induced by hydrochlorothiazide: a rare side effect mimicking myocardial infarction." Br Heart J 63 (1990): 186</p><p id="ref_15">15. Fine SR, Lodha A, Zoneraich S, Mollura JL "Thiazide-induced pulmonary edema." Ann Pharmacother 30 (1996): 416</p><p id="ref_16">16. Fine SR, Lodha A, Zoneraich S, Mollura JL "Hydrochlorothiazide-induced acute pulmonary edema." Ann Pharmacother 29 (1995): 701-3</p><p id="ref_17">17. Goette DK, Beatrice E "Erythema annulare centrifugum caused by hydrochlorothiazide-induced interstitial nephritis." Int J Dermatol 27 (1988): 129-30</p><p id="ref_18">18. Biron P, Dessureault J, Napke E "Acute allergic interstitial pneumonitis induced by hydrochlorothiazide [published erratum appears in Can Med Assoc J 1991 Sep 1;145(5):391]." Can Med Assoc J 145 (1991): 28-34</p><p id="ref_19">19. Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980): 939-43</p><p id="ref_20">20. Prupas HM, Brown D "Acute idiosyncratic reaction to hydrochlorothiazide ingestion." West J Med 138 (1983): 101-2</p><p id="ref_21">21. Grace AA, Morgan AD, Strickland NH "Hydrochlorothiazide causing unexplained pulmonary oedema." Br J Clin Pract 43 (1989): 79-81</p><p id="ref_22">22. Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983): 36-41</p><p id="ref_23">23. Hoss DM, Nierenberg DW "Severe shaking chills and fever following hydrochlorothiazide administration." Am J Med 85 (1988): 747</p><p id="ref_24">24. Geanon JD, Perkins TW "Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide." Arch Ophthalmol 113 (1995): 1231-2</p><p id="ref_25">25. Beaudry C, Laplante L "Severe allergic pneumonitis from hydrochlorothiazide." Ann Intern Med 78 (1973): 251-3</p><p id="ref_26">26. Frierson JH, Marvel SL, Thomas GM "Hydrochlorothiazide-induced pulmonary edema with severe acute myocardial dysfunction." Clin Cardiol 18 (1995): 112-4</p><p id="ref_27">27. Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986): 1456-7</p><p id="ref_28">28. Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987): 161-2</p><p id="ref_29">29. Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973): 992</p><p id="ref_30">30. Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971): 853-63</p><p id="ref_31">31. Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979): 591-4</p><p id="ref_32">32. Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73</p><p id="ref_33">33. Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO, Jr "Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo- controlled, crossover study." Am J Med 94 (1993): 7-12</p><p id="ref_34">34. Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988): 380-5</p><p id="ref_35">35. Mahabir RN, Laufer ST "Clinical evaluation of diuretics in congestive heart failure. A detailed study in four patients." Arch Intern Med 124 (1969): 1-7</p><p id="ref_36">36. Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995): 223-6</p><p id="ref_37">37. Kreisberg RA "Low high-density lipoprotein cholesterol: what does it mean, what can we do about it, and what should we do about it?" Am J Med 94 (1993): 1-6</p><p id="ref_38">38. Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988): 329-31</p><p id="ref_39">39. Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73</p><p id="ref_40">40. Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983): 1017-22</p><p id="ref_41">41. Grunwald MH, Halevy S, Livni E "Allergic vasculitis induced by hydrochlorothiazide: confirmation by mast cell degranulation test." Isr J Med Sci 25 (1989): 572-4</p><p id="ref_42">42. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991): 165-8</p><p id="ref_43">43. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985): 49-51</p><p id="ref_44">44. Robinson HN, Morison WL, Hood AF "Thiazide diuretic therapy and chronic photosensitivity." Arch Dermatol 121 (1985): 522-4</p><p id="ref_45">45. Diffey BL, Langtry J "Phototoxic potential of thiazide diuretics in normal subjects." Arch Dermatol 125 (1989): 1355-8</p><p id="ref_46">46. Rich MW, Eckman JM "Can hydrochlorothiazide cause lupus?" J Rheumatol 22 (1995): 1001</p><p id="ref_47">47. Bjornberg A, Gisslen H "Thiazides: A cause of necrotising vasculitis?" Lancet 2 (1965): 982-3</p><p id="ref_48">48. Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989): 100-2</p><p id="ref_49">49. Brown CW, Deng JS "Thiazide diuretics induce cutaneous lupus-like adverse reaction." J Toxicol Clin Toxicol 33 (1995): 729-33</p><p id="ref_50">50. Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993): 1001-2</p><p id="ref_51">51. Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990): 704-8</p><p id="ref_52">52. Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985): 595-9</p><p id="ref_53">53. Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860</p><p id="ref_54">54. Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995): 133-41</p><p id="ref_55">55. Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4</p><p id="ref_56">56. Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9</p><p id="ref_57">57. Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 48</p><p id="ref_58">58. Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,</p><p id="ref_59">59. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5</p><p id="ref_60">60. Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986): 634</p><p id="ref_61">61. Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971): 828-30</p><p id="ref_62">62. Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985): 1045-59</p><p id="ref_63">63. Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981): 80-3</p><p id="ref_64">64. Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989): 966-9,</p><p id="ref_65">65. Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986): 341</p><p id="ref_66">66. Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990): 739-42</p><p id="ref_67">67. Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 175-6</p><p id="ref_68">68. Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10</p><p id="ref_69">69. Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983): 283-96</p><p id="ref_70">70. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Miettinen OS, Stolley PD "Thiazides and acute cholecystitis." N Engl J Med 303 (1980): 546-8</p><p id="ref_71">71. Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2</p><p id="ref_72">72. Smith BL, Tedeschi A, Lane CD "Pancreatitis with a twist." Hosp Pract (Off Ed) 23 (1988): 150,</p><p id="ref_73">73. Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967): 7-11</p><p id="ref_74">74. Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967): 136-8</p><p id="ref_75">75. Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965): 383-5</p><p id="ref_76">76. Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966): 97-101</p><p id="ref_77">77. Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966): 291-6</p><p id="ref_78">78. Garratty G, Houston M, Petz LD, Webb M "Acute immune intravascular hemolysis due to hydrochlorothiazide." Am J Clin Pathol 76 (1981): 73-8</p><p id="ref_79">79. Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM "Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia." Transfusion 28 (1988): 70-2</p><p id="ref_80">80. Beck ML, Cline JF, Hardman JT, Racela LS, Davis JW "Fatal intravascular immune hemolysis induced by hydrochlorothiazide." Am J Clin Pathol 81 (1984): 791-4</p><p id="ref_81">81. Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973): 1238-9</p><p id="ref_82">82. Eisner EV, Crowell EB "Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody." JAMA 215 (1971): 480-2</p></div>
<div class="more-resources" id="moreResources">
<h2>More about hydrochlorothiazide / valsartan</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>24 Reviews</li>
<li>Drug class: angiotensin II inhibitors with thiazides</li>
<li>FDA Alerts (6)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Valsartan and hydrochlorothiazide &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Diovan HCT</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>High Blood Pressure</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to hydrochlorothiazide / valsartan: oral tablet</i></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, fatigue, dizziness</p><p><b>Rare</b> (less than 0.1%): Vertigo, tinnitus<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Rare</b> (less than 0.1%): Nausea, diarrhea, rash, acute pulmonary edema, interstitial nephritis or cystitis, anaphylaxis<sup>[Ref]</sup></p><p>Rare cases of interstitial nephritis have been associated with the use of HCTZ.  Although HCTZ has been used to treat nephrogenic diabetes insipidus, a case report in which the drug was believed to have caused this condition has been reported.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Rare</b> (less than 0.1%): Renal insufficiency, azotemia<sup>[Ref]</sup></p><p>In multiple-dose studies in hypertensive patients with stable renal insufficiency and renovascular hypertension, the use of valsartan alone had no clinically significant effects of glomerular filtrate rate, filtration fraction, creatinine clearance, or renal plasma flow.  The use of HCTZ has been associated with the development of pre-renal azotemia.  Pretreatment volume repletion is recommended prior to initiating therapy.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Rare</b> (less than 0.1%): Palpitations, chest pain, angioedema</p><p><b>Frequency not reported</b>: Cardiac arrhythmias (including ventricular ectopy and complete AV heart block)<sup>[Ref]</sup></p><p>Chest pain was reported in more than 2% of patients who were taking this combination drug in controlled trials, but this incidence was not significantly different compared with the incidence of chest pain among placebo patients.<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Angiotensin II receptor blockade, unlike ACE inhibition, has no impact on the processing of peptides such as bradykinin and substance P, two peptides able to induce cough.</p><p></p><p>Bronchospasm, dyspnea, and epistaxis have rarely been associated with the use of this drug.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Cough (valsartan component)</p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea, acute pulmonary edema<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Frequency not reported</b>: Erythema annular centrifugum, acute eczematous dermatitis, morbilliform, leukocytoclastic vasculitis, phototoxic dermatitis, subacute cutaneous lupus erythematosus-like condition, pruritus, rash<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Since HCTZ may increase total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, and VLDL lipoprotein cholesterol levels by 50%, and may reduce insulin secretion, it should be used with caution in diabetic patients and in those with hypercholesterolemia.  True glucose intolerance may develop in approximately 3% of patients.  It is typically reversible within six months after discontinuation of therapy.</p><p></p><p>Hyperuricemia may be an important consideration in patients with a history of gout.  Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.<sup>[Ref]</sup></p><p><b>Rare</b> (0.01% to 0.1%): Hypokalemia, hyperkalemia, metabolic alkalosis, hyponatremia, hypomagnesemia, hypercalcemia, hyperglycemia, elevated serum uric acid levels, elevated serum cholesterol<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Thiazide diuretics may increase serum cholesterol and triglycerides, resulting in an increased risk of cholesterol gallstone formation.  Reports of bowel strictures associated with thiazide ingestion were reported in the 1960s (although patients in these reports were on a combination HCTZ-potassium product).<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Diarrhea, constipation, appetite changes, dry mouth, dyspepsia, nausea, vomiting, flatulence, pancreatitis, cholecystitis<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Rare</b> (0.01% to 0.1%): Allergic vasculitis, hemolytic anemia<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Frequency not reported</b>: Glucose intolerance, altered lipid profile<sup>[Ref]</sup></p><p>Use of valsartan alone has not been associated with significant changes in serum lipids or glucose concentrations.  However, use of HCTZ may be associated with increases in total serum cholesterol by 11%, LDL lipoprotein cholesterol by 12%, and VLDL lipoprotein cholesterol levels by 50%.  In addition, use of HCTZ may be associated with reduced insulin secretion.  Therefore, caution is recommended when giving this combination drug to diabetic patients or those with hypercholesterolemia.</p><p></p><p>Hyperuricemia may be an important consideration in patients with a history of gout.  Hypophosphatemia and low serum magnesium concentrations may occur, but are usually clinically insignificant except in malnourished patients.</p><p></p><p>A prospective study of 34 patients who received oral thiazide diuretics for 14 years without interruption revealed significantly increased average fasting blood glucose levels.  Withdrawal of thiazide therapy for 7 months in 10 of the patients resulted in average reductions of 10% in fasting blood glucose and 25% in 2-hour glucose tolerance test values.  A control group was not reported.<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Back pain, muscle cramps, myalgia</p><p></p><p>Valsartan:</p><p><b>Postmarketing reports</b>: Rhabdomyolysis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Neutropenia</p><p><b>Uncommon</b> (0.1% to 1%): Hematocrit decreased, hemoglobin decreased</p><p><b>Rare</b> (0.01% to 0.1%): Immune complex hemolytic anemia</p><p><b>Postmarketing reports</b>: Thrombocytopenia<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Rare</b> (less than 0.1%): Anxiety, depression, decreased libido, insomnia, paresthesias, somnolence<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Rare</b> (less than 0.1%): Impotence, dysuria<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Uncommon</b> (0.1% to 1%): Increases in hepatic enzymes (usually reversible)<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Rare</b> (less than 0.1%): Abnormal vision, idiosyncratic reactions to hydrochlorothiazide resulting in acute transient myopia and acute angle-closure glaucoma<sup>[Ref]</sup></p><p id="ref_1">1. Weir MR, Wright JT, Jr  Ferdinand KC, Cook CA, Champion D, Wong S, Jenkins PA, Kong BW "Comparison of the efficacy and metabolic effects of nicardipine and hydrochlorothiazide in hypertensive black men and women." J Hum Hypertens 7 (1993): 141-7</p><p id="ref_2">2. Langtry HD, McClellan KJ "Valsartan hydrochlorothiazide." Drugs 57 (1999): 751-5</p><p id="ref_3">3. Wellington K,  Faulds DM "Valsartan/Hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension." Drugs 62 (2002): 1983-2005</p><p id="ref_4">4. Gould L, Reddy CV, Zen B, Singh BK "Life-threatening reaction to thiazides." N Y State J Med 80 (1980): 1975-6</p><p id="ref_5">5. Kaplan R, Claudio M, Kepes E, Gu XF "Intravenous guanethidine in patients with reflex sympathetic dystrophy." Acta Anaesthesiol Scand 40 (1996): 1216-22</p><p id="ref_6">6. "Product Information. Diovan HCT (hydrochlorothiazide-valsartan)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_7">7. Holwerda NJ, Fogari R, Angeli P, et al. "Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril." J Hypertens 14 (1996): 1147-115</p><p id="ref_8">8. Oparil S, Dyke S, Harris F, et al. "The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension." Clin Ther 18 (1996): 797-810</p><p id="ref_9">9. Levay ID "Hydrochlorothiazide-induced pulmonary edema." Drug Intell Clin Pharm 18 (1984): 238-9</p><p id="ref_10">10. Klein MD "Noncardiogenic pulmonary edema following hydrochlorothiazide ingestion." Ann Emerg Med 16 (1987): 901-3</p><p id="ref_11">11. Alted E, Navarro M, Cantalapiedra JA, Alvarez JA, Blasco MA, Nunez A "Non-cardiogenic pulmonary edema after oral ingestion of hydrochlorothiazide ." Intensive Care Med 13 (1987): 364-5</p><p id="ref_12">12. Biron P "Thiazide-induced pulmonary edema." Ann Pharmacother 30 (1996): 415-6</p><p id="ref_13">13. Dorn MR, Walker BK "Noncardiogenic pulmonary edema associated with hydrochlorothiazide therapy." Chest 79 (1981): 482-3</p><p id="ref_14">14. Hoegholm A, Rasmussen SW, Kristensen KS "Pulmonary oedema with shock induced by hydrochlorothiazide: a rare side effect mimicking myocardial infarction." Br Heart J 63 (1990): 186</p><p id="ref_15">15. Fine SR, Lodha A, Zoneraich S, Mollura JL "Thiazide-induced pulmonary edema." Ann Pharmacother 30 (1996): 416</p><p id="ref_16">16. Fine SR, Lodha A, Zoneraich S, Mollura JL "Hydrochlorothiazide-induced acute pulmonary edema." Ann Pharmacother 29 (1995): 701-3</p><p id="ref_17">17. Goette DK, Beatrice E "Erythema annulare centrifugum caused by hydrochlorothiazide-induced interstitial nephritis." Int J Dermatol 27 (1988): 129-30</p><p id="ref_18">18. Biron P, Dessureault J, Napke E "Acute allergic interstitial pneumonitis induced by hydrochlorothiazide [published erratum appears in Can Med Assoc J 1991 Sep 1;145(5):391]." Can Med Assoc J 145 (1991): 28-34</p><p id="ref_19">19. Magil AB, Ballon HS, Cameron EC, Rae A "Acute interstitial nephritis associated with thiazide diuretics. Clinical and pathologic observations in three cases." Am J Med 69 (1980): 939-43</p><p id="ref_20">20. Prupas HM, Brown D "Acute idiosyncratic reaction to hydrochlorothiazide ingestion." West J Med 138 (1983): 101-2</p><p id="ref_21">21. Grace AA, Morgan AD, Strickland NH "Hydrochlorothiazide causing unexplained pulmonary oedema." Br J Clin Pract 43 (1989): 79-81</p><p id="ref_22">22. Magil AB "Drug-induced acute interstitial nephritis with granulomas." Hum Pathol 14 (1983): 36-41</p><p id="ref_23">23. Hoss DM, Nierenberg DW "Severe shaking chills and fever following hydrochlorothiazide administration." Am J Med 85 (1988): 747</p><p id="ref_24">24. Geanon JD, Perkins TW "Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide." Arch Ophthalmol 113 (1995): 1231-2</p><p id="ref_25">25. Beaudry C, Laplante L "Severe allergic pneumonitis from hydrochlorothiazide." Ann Intern Med 78 (1973): 251-3</p><p id="ref_26">26. Frierson JH, Marvel SL, Thomas GM "Hydrochlorothiazide-induced pulmonary edema with severe acute myocardial dysfunction." Clin Cardiol 18 (1995): 112-4</p><p id="ref_27">27. Kone B, Gimenez L, Watson AJ "Thiazide-induced hyponatremia." South Med J 79 (1986): 1456-7</p><p id="ref_28">28. Itescu S, Haskell LP, Tannenberg AM "Thiazide-induced clinically significant hypophosphatemia ." Clin Nephrol 27 (1987): 161-2</p><p id="ref_29">29. Delevett AF, Recalde M "Diuretic-induced renal colic." JAMA 225 (1973): 992</p><p id="ref_30">30. Fichman MP, Vorherr H, Kleeman CR, Telfer N "Diuretic-induced hyponatremia." Ann Intern Med 75 (1971): 853-63</p><p id="ref_31">31. Hakim R, Tolis G, Goltzman D, Meltzer S, Friedman R "Severe hypercalcemia associated with hydrochlorothiazide and calcium carbonate therapy." Can Med Assoc J 121 (1979): 591-4</p><p id="ref_32">32. Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73</p><p id="ref_33">33. Miller M, Bachorik PS, McCrindle BW, Kwiterovich PO, Jr "Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo- controlled, crossover study." Am J Med 94 (1993): 7-12</p><p id="ref_34">34. Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G "Ventricular ectopic activity with diuretic therapy." Am J Hypertens 1 (1988): 380-5</p><p id="ref_35">35. Mahabir RN, Laufer ST "Clinical evaluation of diuretics in congestive heart failure. A detailed study in four patients." Arch Intern Med 124 (1969): 1-7</p><p id="ref_36">36. Freis ED "The efficacy and safety of diuretics in treating hypertension." Ann Intern Med 122 (1995): 223-6</p><p id="ref_37">37. Kreisberg RA "Low high-density lipoprotein cholesterol: what does it mean, what can we do about it, and what should we do about it?" Am J Med 94 (1993): 1-6</p><p id="ref_38">38. Krishna GG, Narins RG "Hemodynamic consequences of diuretic-induced hypokalemia." Am J Kidney Dis 12 (1988): 329-31</p><p id="ref_39">39. Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73</p><p id="ref_40">40. Papademetriou V, Fletcher R, Khatri IM, Freis ED "Diuretic-induced hypokalemia in uncomplicated systemic hypertension: effect of plasma potassium correction on cardiac arrhythmias." Am J Cardiol 52 (1983): 1017-22</p><p id="ref_41">41. Grunwald MH, Halevy S, Livni E "Allergic vasculitis induced by hydrochlorothiazide: confirmation by mast cell degranulation test." Isr J Med Sci 25 (1989): 572-4</p><p id="ref_42">42. Mouallem M, Friedman E, Shemesh Y, Mayan H, Pauzner R, Farfel Z "Cardiac conduction defects associated with hyponatremia." Clin Cardiol 14 (1991): 165-8</p><p id="ref_43">43. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA "Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy." Ann Intern Med 103 (1985): 49-51</p><p id="ref_44">44. Robinson HN, Morison WL, Hood AF "Thiazide diuretic therapy and chronic photosensitivity." Arch Dermatol 121 (1985): 522-4</p><p id="ref_45">45. Diffey BL, Langtry J "Phototoxic potential of thiazide diuretics in normal subjects." Arch Dermatol 125 (1989): 1355-8</p><p id="ref_46">46. Rich MW, Eckman JM "Can hydrochlorothiazide cause lupus?" J Rheumatol 22 (1995): 1001</p><p id="ref_47">47. Bjornberg A, Gisslen H "Thiazides: A cause of necrotising vasculitis?" Lancet 2 (1965): 982-3</p><p id="ref_48">48. Parodi A, Romagnoli M, Rebora A "Subacute cutaneous lupus erythematosus-like eruption caused by hydrochlorothiazide." Photodermatol 6 (1989): 100-2</p><p id="ref_49">49. Brown CW, Deng JS "Thiazide diuretics induce cutaneous lupus-like adverse reaction." J Toxicol Clin Toxicol 33 (1995): 729-33</p><p id="ref_50">50. Goodrich AL, Kohn SR "Hydrochlorothiazide-induced lupus erythematosus: a new variant?" J Am Acad Dermatol 28 (1993): 1001-2</p><p id="ref_51">51. Byatt CM, Millard PH, Levin GE "Diuretics and electrolyte disturbances in 1000 consecutive geriatric admissions." J R Soc Med 83 (1990): 704-8</p><p id="ref_52">52. Papademetriou V, Price M, Notargiacomo A, Gottdiener J, Fletcher RD, Freis ED "Effect of diuretic therapy on ventricular arrhythmias in hypertensive patients with or without left ventricular hypertrophy." Am Heart J 110 (1985): 595-9</p><p id="ref_53">53. Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860</p><p id="ref_54">54. Kasiske BL, Ma JZ, Kalil RS, Louis TA "Effects of antihypertensive therapy on serum lipids." Ann Intern Med 122 (1995): 133-41</p><p id="ref_55">55. Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4</p><p id="ref_56">56. Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9</p><p id="ref_57">57. Pinnock CA "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 48</p><p id="ref_58">58. Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,</p><p id="ref_59">59. Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5</p><p id="ref_60">60. Bain PG, Egner W, Walker PR "Thiazide-induced dilutional hyponatraemia masquerading as subarachnoid haemorrhage ." Lancet 2 (1986): 634</p><p id="ref_61">61. Duarte CG, Winnacker JL, Becker KL, Pace A "Thiazide-induced hypercalcemia." N Engl J Med 284 (1971): 828-30</p><p id="ref_62">62. Kuller L, Farrier N, Caggiula A, Borhani N, Dunkle S "Relationship of diuretic therapy and serum magnesium levels among participants in the Multiple Risk Factor Intervention Trial." Am J Epidemiol 122 (1985): 1045-59</p><p id="ref_63">63. Klimiuk PS, Davies M, Adams PH "Primary hyperparathyroidism and thiazide diuretics." Postgrad Med J 57 (1981): 80-3</p><p id="ref_64">64. Peters RW, Hamilton J, Hamilton BP "Incidence of cardiac arrhythmias associated with mild hypokalemia induced by low-dose diuretic therapy for hypertension." South Med J 82 (1989): 966-9,</p><p id="ref_65">65. Benfield GF, Haffner C, Harris P, Stableforth DE "Dilutional hyponatraemia masquerading as subarachnoid haemorrhage in patient on hydrochlorothiazide/amiloride/timolol combined drug ." Lancet 2 (1986): 341</p><p id="ref_66">66. Seelig CB "Magnesium deficiency in two hypertensive patient groups." South Med J 83 (1990): 739-42</p><p id="ref_67">67. Polanska AI, Baron DN "Hyponatraemia associated with hydrochlorothiazide treatment ." Br Med J 1 (1978): 175-6</p><p id="ref_68">68. Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10</p><p id="ref_69">69. Fager G, Berglund G, Bondjers G, Elmfeldt D, Lager I, Olofsson SO, Smith U, Wiklund O "Effects of anti-hypertensive therapy on serum lipoproteins. Treatment with metoprolol, propranolol and hydrochlorothiazide." Artery 11 (1983): 283-96</p><p id="ref_70">70. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Miettinen OS, Stolley PD "Thiazides and acute cholecystitis." N Engl J Med 303 (1980): 546-8</p><p id="ref_71">71. Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2</p><p id="ref_72">72. Smith BL, Tedeschi A, Lane CD "Pancreatitis with a twist." Hosp Pract (Off Ed) 23 (1988): 150,</p><p id="ref_73">73. Wagner W, Longerbeam JK, Smith LL, Feikes HL "Drug-induced ulcers of the small bowel causing intestinal obstruction or perforation." Am Surg 33 (1967): 7-11</p><p id="ref_74">74. Dietz MW "Iatrogenic jejunal ulcer." Am J Roentgenol Radium Ther Nucl Med 99 (1967): 136-8</p><p id="ref_75">75. Holland GW "Stenosing ulcers of the small bowel associated with thiazide and potassium therapy." N Z Med J 64 (1965): 383-5</p><p id="ref_76">76. Reinus FZ, Weinberger HA, Fischer WW "Medication-induced ulceration of the small bowel." Am J Surg 112 (1966): 97-101</p><p id="ref_77">77. Campbell JR, Knapp RW "Small bowel ulceration associated with thiazide and potassium therapy: review of 13 cases." Ann Surg 163 (1966): 291-6</p><p id="ref_78">78. Garratty G, Houston M, Petz LD, Webb M "Acute immune intravascular hemolysis due to hydrochlorothiazide." Am J Clin Pathol 76 (1981): 73-8</p><p id="ref_79">79. Shirey RS, Bartholomew J, Bell W, Pollack B, Kickler TS, Ness PM "Characterization of antibody and selection of alternative drug therapy in hydrochlorothiazide-induced immune hemolytic anemia." Transfusion 28 (1988): 70-2</p><p id="ref_80">80. Beck ML, Cline JF, Hardman JT, Racela LS, Davis JW "Fatal intravascular immune hemolysis induced by hydrochlorothiazide." Am J Clin Pathol 81 (1984): 791-4</p><p id="ref_81">81. Balizet L "Recurrent parathyroid adenoma. Association with prolonged thiazide administration." JAMA 225 (1973): 1238-9</p><p id="ref_82">82. Eisner EV, Crowell EB "Hydrochlorothiazide-dependent thrombocytopenia due to IgM antibody." JAMA 215 (1971): 480-2</p><h2>More about hydrochlorothiazide / valsartan</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>24 Reviews</li>
<li>Drug class: angiotensin II inhibitors with thiazides</li>
<li>FDA Alerts (6)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Valsartan and hydrochlorothiazide &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>High Blood Pressure</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>